Ovarian Cancer
Conditions
Brief summary
The overall aim is to identify effective therapeutic strategies to ovarian cancer (OC) using serial tumor, ascites and blood samples, and carry out state-of-the-art sequencing approaches, functional assays and associated bioinformatics to understand mechanisms behind chemoresistance in OC and identify new treatment options for OC patients. In this observational trial, we will systematically collect, analyze and interpret functional, molecular and clinical data from real-world ovarian cancer patients.
Interventions
GENETICBiomolecular profiling
Molecular and functional analysis of biospecimens, including tumor-normal Whole-exome sequencing, bulk and single-cell RNAsequencing, spatial proteomics, functional testing.
Sponsors
Helsinki University Central Hospital
University of Helsinki
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with ovarian cancer * Available tumor tissue/blood samples
Exclusion criteria
* Inability to consent to the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recruitment and collection of real-world clinical data from ovarian cancer patients | 5 years | Prospective recruitment and collection of clinical data from 500 ovarian cancer patients. Fraction of patients from which the collection of clinical data including patient age, tumor stage, histological diagnoses have been collected. |
| Successful collection and translational analysis of biospecimens | 5 years | Fraction of the recruited patients, from which tumor, ascites, and/or peripheral blood samples that have been successfully collected and subjected to molecular profiling. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Discovery of candidate prognostic and predictive biomarkers | 5 years | Number of clinical and/or molecular features which of statistically significantly correlate to patient treatment outcomes (response to chemotherapy by RECIST1.1, Progression Free survival, Overall Survival). |
Countries
Finland
Contacts
Primary ContactAnniina Färkkilä, MD PhD
Outcome results
None listed